Biological And Clinical Study Of Dicitabine Combined With Chemotherapy In The Treatment Of TP53 Mutation Diffuse Large B-cell Lymphoma

Objective:1.To observe the effect of DAC on the proliferation,apoptosis and cell cycle of TP53-mutant DLBC L cell line.2.The efficacy and safety of DAC combined with chemotherapy in the treatment of patients with relapsed refractory TP53 mutation DLBC L were observed.Methods:1.Selected DLBC L cell line TP53 wild-type OCI-LY3 and mutant DB for culture,and plotted the growth curve.2.Cell proliferation inhibition rate was detected using CCK-8 method and IC50 concentration was calculated.3.Detection of apoptosis rate and cell cycle by flow cytometry.4.Statistical analysis compared the differences in ce ll proliferation,apoptosis and cycle within and between subgroups.5.Clinical data of five patients with relapsed refractory TP53 mutation DLBCL treated with DAC combined with second-line regimen were collected for retrospective summary.Results:1.Dicitabine has an inhibitory effect on the proliferation of DB cell lines,and with the increase of drug concentration,the inhibition rate after the combination of the two drugs is significantly higher than that of single drugs.2.The inhibitory effect of dicitabine on DB cell lines gradually increases with time.3.ADM and DAC can induce apoptosis of DB cells,and the apoptosis rate increases after the combination of the two drugs,and early apoptosis is the mainstay.4.ADM and DAC can affect the DB cell cycle progress,the action of 24 h shows S phase block,the action of 48 h shows G2/M phase block,accompanied by cells in G0 /G1 stage with the increase of action time and decrease.5.After treatment with DAC-included regimens,the total effective rate of treatment in 5 patients with relapsed refractory DLBC L was 40%(2/5),the main adverse effect was bone marrow suppression,and there was no treatment-related death.Conclusion:1.Dicitabine has a concentration-and time-dependent value-added inhibition effect on TP53-mutant DLBCL cell lines,and promotes their apoptosis and blocks the cell cycle.2.Dicitabine combined with chemotherapy in the treatment of TP53 mutation recurrence refractory diffuse large B-cell lymphoma have a certain efficacy and good safety,which is worth further exploration.